Verrica Pharmaceuticals, Inc.(NASDAQ : VRCA)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||1.99%||156.12||0.7%||$1151.45m|
|MRK||Merck & Co., Inc.||1.34%||73.14||0.7%||$859.53m|
|BMY||Bristol-Myers Squibb Co.||1.75%||60.38||1.0%||$833.94m|
|LLY||Eli Lilly & Co.||3.13%||206.81||1.1%||$635.54m|
|KALV||KalVista Pharmaceuticals, Inc.||-2.16%||30.88||0.4%||$99.62m|
|NVO||Novo Nordisk A/S||0.58%||69.62||0.1%||$91.37m|
Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.